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REPLY
We appreciate Dr. Lengyel’s interest in our PRO-TEE study
regarding thrombolysis of prosthetic valve thrombosis (PVT) (1).
In this international registry, thrombus burden was found to be the
best predictor of complications in addition to a previous history of
stroke. A thrombus area of 0.8 cm2 identified a threshold beyond
which complications increased, irrespective of functional class.
Thus, thrombolysis is safest in patients with thrombi 0.8 cm2
and no previous stroke. In patients with larger thrombi, recom-
mendation of thrombolysis versus repeat surgery depends on the
relative risk of each modality in a particular patient (1).
Dr. Lengyel proposes to use thrombolysis in all patients with
PVT, irrespective of thrombus size and functional class. This is
mostly based on a series of prosthetic valves reported by Lengyel
and Vándor (2) where 43 cases underwent thrombolysis and 20
underwent surgery. Mortality rate was lower with thrombolysis (2
of 43 or 5% vs. 6 of 20 or 30%). However, patients were selected to
undergo surgery as opposed to thrombolysis if they had a left atrial
thrombus, if they presented with a stroke, or if they failed
thrombolysis. This selection most likely contributed to the higher
mortality rate of the small surgical group and to the lower mortality
of the thrombolysis group. Furthermore, it is difficult to negate the
relation of thrombus burden to complications of thrombolysis in
that study because thrombus length was measured in only 3 of the
30 cases of obstructed valves. In the “nonobstructed” valves, the
majority of which were in New York Heart Association functional
class I and II, the thrombus length was generally small. Thrombus
area was not measured. We disagree with the statement that
thrombus burden cannot be measured with transesophageal echo-
cardiography (TEE) when the valve is obstructed. Indeed, this was
feasible in the PRO-TEE study where we found that thrombus
area was a better discriminator than thrombus length in predicting
complications. Whether three-dimensional echocardiography dur-
ing TEE further refines the quantitation of thrombus burden and
the risk of thrombolysis remains to be determined.
Dr. Lengyel also relates that recent experience with thrombol-
ysis (1996 to 2003) shows a lower incidence of embolic phenomena
(4%) and death rate (2.5%) compared to earlier experience. These
complication rates are quite low compared to most reported series,
including Dr. Lengyel’s (1–3). While the exact reasons for this
difference may not be readily apparent, imaging with TEE prior to
management decision and avoidance of patients at high risk with
large thrombi are likely contributing factors. In fact, in PRO-
TEE, the use of thrombolysis irrespective of thrombus size in some
centers provided a wide range of thrombus burden and allowed the
evaluation of the relation of thrombus size to complications. The
complication rate observed in PRO-TEE (embolic rate: 14%;
death rate: 5.6%) was similar to reported series not using TEE to
guide therapy, pointing to less selection bias.
Thus, we maintain that TEE is essential in the management of
patients with suspected PVT. The PRO-TEE registry, although
retrospective, identified for the first time the threshold of a “small
clot” beyond which risk of complications increases with thrombol-
ysis. Thrombolysis has the least complications with thrombi 0.8
cm2 and no previous stroke. In these patients, thrombolysis in our
opinion should be a first-line therapy, regardless of functional
class, unless contraindications are present. With larger thrombi,
risk of complications appears to be incremental. Although throm-
bolysis is not an absolute contraindication in patients with larger
thrombi, the choice of thrombolysis versus repeat surgery in these
patients depends on the relative risk of each modality in a
particular patient and institution. These recommendations await
further validation in a prospective multicenter trial.
Ann T. Tong, MD, FACC
Raymond Roudaut, MD
Mehmet Özkan, MD
Alex Sagie, MD
Maie S. A. Shahid, MD
Sergio C. Pontes, Jr, MD
Francesc Carreras, MD
Steven E. Girard, MD, FACC
Samir Arnaout, MD
Raymond F. Stainback, MD, FACC
Ravi Thadani, MD, MPH
*William A. Zoghbi, MD, FACC
on behalf of the PRO–TEE Registry Investigators
*Baylor College of Medicine
6550 Fannin
SM677
Houston
Texas 77030
E-mail: wzoghbi@bcm.tmc.edu
doi:10.1016/j.jacc.2004.10.029
REFERENCES
1. Tong AT, Roudaut R, Özkan M, et al., on behalf of the Prosthetic
Valve Thrombolysis-Role of Transesophageal Echocardiography
(PRO-TEE) registry investigators. Transesophageal echocardiography
improves risk assessment of thrombolysis of prosthetic valve thrombosis:
results of the international PRO-TEE registry. J Am Coll Cardiol
2004;43:77–84.
2. Lengyel M, Vándor L. The role of thrombolysis in the management of
left-sided prosthetic valve thrombosis: a study of 85 cases diagnosed by
transesophageal echocardiography. J Heart Valve Dis 2001;10:636–49.
3. Roudaut R, Lafitte S, Roudaut MF, et al. Fibrinolysis of mechanical
prosthetic valve thrombosis: a single-center study of 127 cases. J Am
Coll Cardiol 2003;41:659–60.
Cardiologist in the Carotids
I read with interest the viewpoint by Dr. Gray (1), which reviews
the case for carotid stenting. As an emerging technology, carotid
stenting can be an important therapeutic modality for high surgical
risk patients, and has the potential for expanded applications in
additional patient groups.
What is the cardiac surgeon’s role in the development and
dissemination of carotid stents? Should one specialty alone be a
gatekeeper for the introduction and performance of new endovas-
cular procedures? Dr. Gray argues that cardiologists should be at
the forefront of the wave to deploy endoluminal stents for carotid
artery disease owing to their familiarity with complex percutaneous
interventional procedures, and their ability to manage carotid-
body–related medical issues. Cardiac and vascular surgeons are
similarly capable of performing the technically demanding skills
involved in carotid stenting, and they are also qualified to handle
the postprocedure medical sequelae. Cardiac and vascular sur-
geons, in contrast to cardiologists, are capable of managing
life-threatening and device-related surgical complications. How-
ever, catheter-based skills are absent from the curriculum of most
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